1-3 of 3
Ruth Plummer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL

Graham P. Collins, William Townsend, Ahmed Abdulgawad, Swathi Namburi, Anja Williams, Ana Filipa Palma DosReis, Matthew G. Krebs, Jeff Evans, Sarah P. Blagden, Ruth Plummer, Daniel Hochhauser, Adam Sharp, George Cole, Seema Rogers, Daniel Chan, Sarah Whelan, Dima El-Sharkawi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3093.
https://doi.org/10.1182/blood-2023-172875
Published: 2023
Journal Articles

Inhibition of ATR in Combination with Nucleoside Analogues Eradicates Acute Myeloid Leukaemia in an Orthotopic Murine Xenograft Model

Sarah E Fordham, PhD, Helen J Blair, PhD, Claire J Elstob, PhD, Deepali Pal, PhD, Nicola Curtin, PhD, Paul Milne, PhD, Matthew Collin, MD PhD, Graham H Jackson, MD MBBS, Helen J Marr, MD PhD, Olaf Heidenreich, PhD, Ruth Plummer, John Pollard, PhD, Tobias F. Menne, MD PhD FRCPath, Gail L Jones, MD BMBS, James M Allan, DPhil
Journal: Blood
Blood (2016) 128 (22): 4031.
https://doi.org/10.1182/blood.V128.22.4031.4031
Published: 2016
Journal Articles

A Phase 1 Study Evaluating Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Advanced Malignancies and Varying Degrees of Hepatic Impairment (HI)

Jennifer Brown, Ruth Plummer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou, Ulka Vaishampayan
Journal: Blood
Blood (2016) 128 (22): 4496.
https://doi.org/10.1182/blood.V128.22.4496.4496
Published: 2016